Developing New Ways to Activate cGAS-STING for Cancer Immunotherapy
Injecting molecular danger signals into a tumor can trigger strong anti-tumor immune responses. It is especially promising to activate the cGAS-STING innate immune pathway, which detects the danger signal of cytosolic DNA. Therapeutic activation of this pathway in preclinical models is typically achieved using small molecules that activate STING. We aim to improve the efficacy and toxicity of this therapy by developing new therapeutics that activate the upstream sensor cGAS instead.